Drug Profile
Umitrelimorgene autodencel - Duke University Medical Center/Immunomic Therapeutics
Alternative Names: Cancer vaccine pp65 - Immunomic Therapeutics/Duke University; CMV pp65-LAMP mRNA-loaded dendritic cells; CMV RNA-Pulsed dendritic cells; Cytomegalovirus pp65-LAMP mRNA-loaded dendritic cells; flLAMP-pp65; ITI-1000; LAMP + pp65 DC; pp65-flLAMP DC; pp65-shLAMP DC; shLAMP-pp65Latest Information Update: 22 Jan 2024
Price :
$50
*
At a glance
- Originator Duke University Medical Center; Immunomic Therapeutics
- Developer Duke University Medical Center; National Cancer Institute (USA); University of Florida
- Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glioblastoma
Most Recent Events
- 12 Jan 2024 Immunomic Therapeutics and University of Florida terminates the RENEW phase I trial for Glioblastoma (Newly-diagnosed) in the US as per sponsor decision (NCT04963413)
- 30 Nov 2023 University of Florida and the National Cancer Institute completes a phase II ATTAC-II trial in Glioblastoma (Newly diagnosed) in USA (Intradermal) (NCT02465268)
- 23 Mar 2023 Duke University Medical Center completes the phase I/II ATTAC trial for Glioblastoma (Newly diagnosed) in USA (Interadermal) (NCT00639639)